CD8 T-Cell Responses before and after Structured Treatment Interruption in Ugandan Adults Who Initiated ART with CD4 T Cells <200 Cell/μL: The DART Trial STI Substudy
- PMID: 21490785
- PMCID: PMC3065901
- DOI: 10.1155/2011/875028
CD8 T-Cell Responses before and after Structured Treatment Interruption in Ugandan Adults Who Initiated ART with CD4 T Cells <200 Cell/μL: The DART Trial STI Substudy
Abstract
Objective. To better understand attributes of ART-associated HIV-induced T-cell responses that might be therapeutically harnessed. Methods. CD8(+) T-cell responses were evaluated in some HIV-1 chronically infected participants of the fixed duration STI substudy of the DART trial. Magnitudes, breadths, and functionality of IFN-γ and Perforin responses were compared in STI (n = 42) and continuous treatment (CT) (n = 46) before and after a single STI cycle when the DART STI trial was stopped early due to inferior clinical outcome in STI participants. Results. STI and CT had comparable magnitudes and breadths of monofunctional CD8(+)IFNγ(+) and CD8(+)Perforin(+) responses. However, STI was associated with significant decline in breadth of bi-functional (CD8(+)IFNγ(+)Perforin(+)) responses; P = .02, Mann-Whitney test. Conclusions. STI in individuals initiated onto ART at <200 CD4(+) T-cell counts/μl significantly reduced occurrence of bifunctional CD8(+)IFNγ(+)/Perforin(+) responses. These data add to others that found no evidence to support STI as a strategy to improve HIV-specific immunity during ART.
Figures




Similar articles
-
Fixed duration interruptions are inferior to continuous treatment in African adults starting therapy with CD4 cell counts < 200 cells/microl.AIDS. 2008 Jan 11;22(2):237-47. doi: 10.1097/QAD.0b013e3282f2d760. AIDS. 2008. PMID: 18097226 Clinical Trial.
-
Structured treatment interruption in chronically HIV-1 infected patients after long-term viral suppression.AIDS. 2000 Mar 10;14(4):397-403. doi: 10.1097/00002030-200003100-00013. AIDS. 2000. PMID: 10770542
-
Continuous versus intermittent treatment strategies during primary HIV-1 infection: the randomized ANRS INTERPRIM Trial.AIDS. 2012 Sep 24;26(15):1895-905. doi: 10.1097/QAD.0b013e32835844d9. AIDS. 2012. PMID: 22842994 Clinical Trial.
-
Structured treatment interruption in patients infected with HIV: a new approach to therapy.Drugs. 2002;62(2):245-53. doi: 10.2165/00003495-200262020-00001. Drugs. 2002. PMID: 11817971 Review.
-
[The current status of structured treatment interruption].Nihon Rinsho. 2002 Apr;60(4):807-12. Nihon Rinsho. 2002. PMID: 11968793 Review. Japanese.
Cited by
-
CD8+ T-Cell Response to HIV Infection in the Era of Antiretroviral Therapy.Front Immunol. 2019 Aug 9;10:1896. doi: 10.3389/fimmu.2019.01896. eCollection 2019. Front Immunol. 2019. PMID: 31447862 Free PMC article. Review.
-
Frequencies of Gag-restricted T-cell escape "footprints" differ across HIV-1 clades A1 and D chronically infected Ugandans irrespective of host HLA B alleles.Vaccine. 2015 Mar 30;33(14):1664-72. doi: 10.1016/j.vaccine.2015.02.037. Epub 2015 Feb 26. Vaccine. 2015. PMID: 25728323 Free PMC article.
References
-
- Mollet L, Li T-S, Samri A, et al. Dynamics of HIV-specific CD8+ T lymphocytes with changes in viral load. Journal of Immunology. 2000;165(3):1692–1704. - PubMed
-
- Gray CM, Lawrence J, Schapiro JM, et al. Frequency of class I HLA-restricted anti-HIV CD8+ T cells in individuals receiving highly active antiretroviral therapy (HAART) Journal of Immunology. 1999;162(3):1780–1788. - PubMed
-
- Alatrakchi N, Duvivier C, Costagliola D, et al. Persistent low viral load on antiretroviral therapy is associated with T cell-mediated control of HIV replication. AIDS. 2005;19(1):25–33. - PubMed
-
- Nicastri E, Leone S, Angeletti C, et al. Sex issues in HIV-1-infected persons during highly active antiretroviral therapy: a systematic review. Journal of Antimicrobial Chemotherapy. 2007;60(4):724–732. - PubMed
Grants and funding
LinkOut - more resources
Full Text Sources
Research Materials